In conclusion, while combining PD-1 and CTLA-4 blockade (nivo/ipi) or PD-1 and KIR blockade (nivo/liri) is feasible in patients with advanced lymphoma and MM, the combination of nivo/ipi appears to be associated with increased but manageable toxicity over that expected with single-agent nivolumab. The gene discussed is CTLA4; the disease is Miyoshi myopathy.